John C. Lechleiter, Ph.D.
Chairman, President, and Chief Executive Officer
Eli Lilly and Company
John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008. He became chairman of the board of directors on January 1, 2009.
Lechleiter joined Lilly in 1979 as a senior organic chemist in process research and development and became head of that department in 1982. In 1984, he began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England.
He returned to the United States in 1986 as manager of research and development projects for Europe. In 1988, he became director of development projects management, and he assumed additional responsibility for pharmaceutical regulatory affairs the following year. In 1991, Lechleiter was named executive director of pharmaceutical product development, and he became vice president in 1993. He was appointed vice president of regulatory affairs in 1994, was named vice president for development and regulatory affairs in 1996, and became senior vice president of pharmaceutical products in 1998.
In 2001, Lechleiter was appointed executive vice president for pharmaceutical products and corporate development. In 2004, he became Lilly’s executive vice president for pharmaceutical operations. And in 2005, he was named president and chief operating officer and joined the board of directors.
Lechleiter received a bachelor of science degree in chemistry from Xavier University (Cincinnati, Ohio) in 1975. He subsequently studied organic chemistry as a National Science Foundation Fellow at Harvard University, where he received his master’s and doctorate degrees in 1980. Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, and the National University of Ireland.
Lechleiter is a member of the American Chemical Society and Business Roundtable. Dr. Lechleiter serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as chairman of the U.S.-Japan Business Council, and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the boards of Nike, Inc. and Ford Motor Company.
Skylark Co., Ltd.
Ralph Alvarez is executive chairman of Skylark Co., Ltd., a leading restaurant operator in Japan. He was elected to the board of directors of Eli Lilly and Company in 2009.
Born in Cuba, he received his bachelor’s degree in business administration from the University of Miami.
Mr. Alvarez retired as president and chief operating officer of McDonald’s Corporation in 2009. Prior to joining McDonald’s in 1994, he held leadership positions at Burger King Corporation and Wendy’s International, Inc. He held a variety of leadership roles throughout his career, including chief operations officer and president of the central division, both with McDonald’s USA. Before joining the U.S. business, Alvarez was president of McDonald’s Mexico. From July 2004 until January 2005, he was president of McDonald’s USA, where he led a team that aligned employees, owner/operators, and suppliers behind the company’s “Plan to Win” strategy – the catalyst for the turnaround of the U.S. business. Alvarez served as president of McDonald’s North America from January 2005 until August 2006. In this role, he was responsible for all the McDonald’s restaurants in the U.S. and Canada. Alvarez became president and chief operating officer in August 2006. He set the global strategy and directed operations for 32,000 McDonald’s restaurants in 118 countries.
Mr. Alvarez is an active advocate for education. He serves on the President’s Council, the School of Business Administration Board of Overseers, and the International Advisory Board of the University of Miami. Mr. Alvarez is also a current member of the board of directors of Skylark Co., Ltd., Lowe’s Companies, Inc., and Dunkin’ Brands Group, Inc. He also served on the board of McDonald’s Corporation and KeyCorp.
Katherine Baicker, Ph.D.
Professor of Health Economics
Katherine Baicker, Ph.D., is professor of health economics at the Harvard University School of Public Health, Department of Health Policy and Management. She is also a research associate at the National Bureau of Economic Research. She was elected to the Eli Lilly and Company board of directors in December 2011.
Baicker received a bachelor of arts degree in economics, magna cum laude, from Yale University in 1993, and a Ph.D. in economics from Harvard University in 1998.
From 1998 to 2005, Baicker was assistant professor and associate professor of economics at Dartmouth College. In 2001 and 2002 she also served as a senior economist to the Council of Economic Advisers, Executive Office of the President, and in 2003 was a visiting assistant professor at the University of Chicago Harris School of Public Policy. From 2005 to 2007, she served as a Senate-confirmed member of the Council of Economic Advisers, where she played a leading role in the development of health policy. In 2007, she joined Harvard as professor of health economics at the Department of Health Policy and Management, School of Public Health.
Baicker is a commissioner of the Medicare Payment Advisory Board and serves on the Panel of Health Advisers to the Congressional Budget Office. She is a member of the editorial boards of Health Affairs and the Journal of Health Economics; chair of the board of directors of AcademyHealth; editor of the Forum for Health Economics and Policy; and associate editor of the Journal of Economic Perspectives. She is an elected member of the Institute of Medicine.
Sir Winfried Bischoff
Lloyds Banking Group plc
Sir Winfried Bischoff is chairman of Lloyds Banking Group plc. He was elected to the board of directors of Eli Lilly and Company in 2000.
After early education in Cologne and Dusseldorf, Germany, he moved to South Africa in 1955 and obtained a bachelor of commerce degree at the University of the Witwatersrand in Johannesburg in 1961. From 1962 to 1963, he was attached to the international department of Chase Manhattan Bank in New York.
Bischoff joined the company finance division of J. Henry Schroder & Co. Limited, London (the London Investment Bank of the Schroder Group) in 1966 and transferred to the bank’s international issues department in 1970. The next year, he was appointed managing director of Schroders Asia Limited, Hong Kong. In 1983, he returned to London in charge of the company finance division of J. Henry Schroder & Co. He was appointed chairman of J. Henry Schroder & Co. in 1983, and, in addition, group chief executive of Schroders plc in 1984. In 1995, he was named chairman of Schroders plc. Following the acquisition of Schroders’ investment banking business by Citigroup, he served as chairman of Citigroup Europe from 2000 to 2009. He served as chairman of Citigroup Inc. from December 2007 until February 2009. He was appointed to his present position on September 15, 2009.
He is a nonexecutive director of The McGraw-Hill Companies, Inc. He is a past member of the boards of Siemens Holdings plc; Cable and Wireless plc; IFIL Finanziaria di Partecipazioni SPA, Italy; Land Securities plc; Prudential plc; and AkBank T.A.S., Turkey.
He is chairman of The Advisory Council of The City UK. He was awarded a knighthood for service to the banking industry in the New Year Honours list in 2000.
Michael L. Eskew
Former Chairman and Chief Executive Officer
United Parcel Service, Inc.
Michael L. Eskew is the retired chairman and chief executive officer of United Parcel Service, Inc., a position he held from January 2002 until December 2007. He continues to serve on the UPS board of directors. He was elected to the Eli Lilly and Company board of directors in 2008.
A native of Vincennes, Indiana, Eskew graduated from Purdue University with a bachelor’s degree in industrial engineering. He also completed the advanced management program at the Wharton School of Business.
Eskew serves as the chairman of the board of trustees of The Annie E. Casey Foundation, which is the country’s largest foundation dedicated to disadvantaged youth. He also serves on the boards of directors of the 3M Corporation and IBM Corporation.
J. Erik Fyrwald
President and Chief Executive Officer
J. Erik Fyrwald joined Univar Inc. in May 2012 as its president and chief executive officer. In 2008, following a 27-year career at DuPont, he joined Nalco Company, serving as chairman and chief executive officer until 2011, when Nalco merged with Ecolab Inc. Following the merger, Fyrwald served as president of Ecolab. He was elected to the Eli Lilly and Company board of directors in 2005.
From 2003 to 2008, Fyrwald served as group vice president of the agriculture and nutrition division at E.I. du Pont de Nemours and Company. From 2000 until 2003, he was vice president and general manager of DuPont’s nutrition and health business.
Fyrwald attended the University of Delaware, where he received a bachelor of science degree in chemical engineering in 1981. He also completed the advanced management program at Harvard Business School.
Fyrwald serves as a director of Univar Inc., the Society of Chemical Industry, the American Chemistry Council, and the Chicago Public Education Fund, and is a trustee of the Field Museum of Chicago.
Alfred G. Gilman, M.D., Ph.D.
Regental Professor of Pharmacology Emeritus
University of Texas Southwestern Medical Center
Born in New Haven, Connecticut, he received a bachelor of science degree summa cum laude in biochemistry in 1962 from Yale University and his doctor of medicine degree and doctorate in pharmacology in 1969 from Case Western Reserve University. He received further training as a pharmacology research associate in the Laboratory of Biochemical Genetics at the National Institutes of Health beginning in 1969. In 1971, he began a ten-year stay at the University of Virginia School of Medicine in Charlottesville where his positions included assistant, associate, and professor of pharmacology, and director of the medical scientist training program.
Gilman then served as professor and chairman of the Department of Pharmacology at the University of Texas Southwestern Medical Center (Dallas) from 1981 to 2005. He was dean of Southwestern Medical School from 2004 to 2009 and provost and executive vice president for academic affairs of Southwestern Medical Center from 2006 to 2009. He was chief scientific officer of the Cancer Prevention and Research Institute of Texas (CPRIT) from 2009 to 2012. CPRIT was established by a state constitutional amendment and empowered to spend up to $3 billion over 10 years on cancer research and prevention in the state of Texas.
He is a member of the board of directors of Regeneron Pharmaceuticals, Inc. He was the editor of Goodman and Gilman’s The Pharmacological Basis of Therapeutics from 1980 to 1990.
Gilman has been the recipient of many awards including: the Nobel Prize in Physiology or Medicine (1994), American Heart Association Basic Science Research Prize (1990), American Cancer Society Medal of Honor (1995), Albert Lasker Basic Medical Research Award (1989), election to the National Academy of Sciences (1985), and The Gairdner Foundation International Award (1984). He has received honorary degrees from the University of Chicago (1990), Case Western Reserve University (1995), Yale University (1997), and the University of Miami (1999).
R. David Hoover
R. David Hoover is chairman of Ball Corporation, a provider of high-quality packaging for beverage, food, and household products customers, and of aerospace and other technologies and services, primarily for the U.S. government. He was elected to the board of directors of Eli Lilly and Company in 2009.
A native of Straughn, Indiana, he received a bachelor’s degree in economics from DePauw University in 1967 and his MBA in finance and real estate from Indiana University in 1970. He also completed the advanced management program at Harvard University Graduate School of Business, Boston, in 1988.
Hoover was the chairman, president, and chief executive officer of Ball Corporation from April 2002 until January 2010 having been elected president and chief executive officer in January 2001. He was chairman and chief executive officer until January 2011. Hoover joined Ball Corporation in 1970. During his career, he has served as vice president, finance and administration, of both the company’s agricultural systems division and the company’s aerospace systems group. He was elected vice president and treasurer in 1988 and senior vice president and chief financial officer in 1992. He was named executive vice president and elected to the company’s board of directors in 1996. In 1998, he was elected vice chairman, in addition to the role of chief financial officer. Hoover became president of Ball Corporation in January 2000, and was named chief operating officer in April 2000.
Hoover is a member of the boards of Ball Corporation and Energizer Holdings, Inc. He is a member of the board of the National Association of Manufacturers and is a member and past chair of the board of governors of the Can Manufacturers Institute (CMI). Hoover is a member and past chair of the board of trustees of DePauw University and on the Indiana University Kelley School of Business Dean’s Council. He is also a director of Boulder Community Hospital and a member of the Colorado Forum.
Karen N. Horn, Ph.D.
Retired President, Private Client Services, and Managing Director
Karen N. Horn, Ph.D., served as president, private client services, and managing director of Marsh, Inc. from 1999 until her retirement in 2003. She was elected to the board of directors of Eli Lilly and Company in 1987.
She earned a bachelor of arts degree in mathematics and economics from Pomona College and holds a doctor of philosophy degree in economics from The Johns Hopkins University. Her previous experience includes senior managing director and head of international private banking, Bankers Trust Company; chairman and chief executive officer of Bank One, Cleveland, N.A.; president of the Federal Reserve Bank of Cleveland; treasurer of Bell Telephone Company of Pennsylvania; and vice president of First National Bank of Boston.
Horn has been senior managing director of Brock Capital Group since 2004. She is a director of T. Rowe Price Mutual Funds; The U.S. Russia Investment Fund, a presidential appointment; Simon Property Group, Inc.; Norfolk Southern Corporation, and vice chairman of the U.S. Russia Foundation. Also, she served on the President’s Bipartisan Commission on Entitlements.
William G. Kaelin, Jr., M.D.
Professor, Department of Medicine and Associate Director, Basic Science
Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dana-Farber/Harvard Cancer Center
William G. Kaelin, Jr., M.D., is professor in the Department of Medicine at the Dana-Farber Cancer Institute and at the Brigham and Women’s Hospital, Harvard Medical School. He currently serves as associate director, Basic Science, for the Dana-Farber/Harvard Cancer Center. He was elected to the board of directors of Eli Lilly and Company in June 2012.
Kaelin received his degree in medicine from Duke University in 1982 and was a house officer and chief resident in internal medicine at Johns Hopkins Hospital. He was a medical oncology clinical fellow at Dana-Farber and a postdoctoral fellow in the laboratory of Dr. David Livingston, where he began his studies of tumor suppressor proteins. He became an independent investigator at Dana-Farber in 1992 and a Howard Hughes Medical Institute investigator and professor of Medicine at Harvard Medical School in 2002.
Kaelin is a member of the American Society of Clinical Investigation (ASCI) and the American College of Physicians. He recently served on the National Cancer Institute Board of Scientific Advisors, the American Association for Cancer Research (AACR) Board of Trustees, and the Institute of Medicine National Cancer Policy Board. He is a recipient of the Paul Marks Prize for cancer research from the Memorial Sloan-Kettering Cancer Center, the Richard and Hinda Rosenthal Prize from the AACR, and a Doris Duke Distinguished Clinical Scientist award. In 2007 he was elected to the Institute of Medicine. In 2010, Kaelin was elected to the National Academy of Sciences and was a recipient of the 2010 Canada International Gairdner Award. In 2011 he received the Alfred Knudson Lecture in Cancer Genetics award, and in 2012 Kaelin was a co-recipient of both the ASCI’s Stanley J. Korsmeyer Award and the Scientific Grand Prix of the Foundation Lefoulon-Delalande. In 2012 Kaelin was elected to the Association of American Physicians.
Ellen R. Marram
The Barnegat Group LLC
Ellen R. Marram is the president of The Barnegat Group LLC, a firm that provides business advisory services. She was a managing director at North Castle Partners, LLC from 2000 to 2005 and an advisor to the firm from 2006 to 2010. Marram has been a member of the board of directors of Eli Lilly and Company since 2002. She was elected lead independent director effective April 2012.
From 1993 to 1998, Marram was president and chief executive officer of Tropicana and the Tropicana Beverage Group. She steadily grew revenue and earnings and nearly doubled margins as she transformed Tropicana from a Florida juice company to a market-driven, health-focused, global juice business, number one in worldwide sales and profits. During Marram’s tenure, Tropicana nearly tripled its shareholder value and was sold to PepsiCo in 1998 for $3.3 billion.
From 1988 to 1993, Marram was president and chief executive officer of the Nabisco Biscuit Company, the largest operating unit of Nabisco, Inc. Under her leadership, the company significantly increased sales and margins and had one of the most successful new product records in the food industry. Marram’s vision and direction led to the 1992 launch of SnackWell’s cookies and crackers, which pioneered low fat snacking and is considered one of the most successful new products of the 1990s.
From 1987 to 1988, Marram was president of Nabisco’s grocery division. From 1970 to 1986, she held a series of marketing positions at Nabisco/Standard Brands, Johnson & Johnson, and Lever Brothers.
Marram is a member of the board of directors of Ford Motor Company and The New York Times Company, as well as several private companies. She also serves on the boards of Wellesley College, Institute for the Future, New York-Presbyterian Hospital, Lincoln Center Theater, and Families and Work Institute. She is a past member of the board of associates of Harvard Business School and a past trustee of the Conference Board.
She is a 1968 graduate of Wellesley College and earned an MBA in 1970 from Harvard Business School, and has received alumni achievement awards from both institutions. She was named one of the Top 25 Managers of the Year by Business Week in January 1998.
Douglas R. Oberhelman
Chairman and Chief Executive Officer
Douglas R. Oberhelman is chairman and chief executive officer of Caterpillar Inc. in Peoria, Illinois. He was elected to the Eli Lilly and Company board of directors in 2008.
Oberhelman was elected a vice president in 1995, serving as Caterpillar’s chief financial officer with administrative responsibility for the corporation’s accounting, information services, tax, treasury, investor relations, and marketing support services areas from 1995 to November 1998. In 1998, he became vice president with responsibility for the engine products division, including the market development, strategic planning, supplier management, electric power generation, and worldwide marketing and administration for Caterpillar’s engine business. He was elected a group president and member of Caterpillar’s executive office in 2002. Oberhelman became vice chairman and chief executive officer-elect in January 2010.
Oberhelman joined Caterpillar in 1975 and has held a variety of positions, including senior finance representative based in South America for Caterpillar Americas Co; region finance manager and district manager for the company’s North American commercial division; and managing director and vice general manager for strategic planning at Caterpillar Japan Ltd.
He has a bachelor’s degree from Millikin University. He has served as chairman of the board of trustees for Millikin University and chairman of the board of directors for Easter Seals, and he is a former director for the boards of Ameren Corporation, South Side Bank, Millikin University, and Easter Seals. He is chairman of the board of Caterpillar. He is also a member of the board of directors and vice chairman of the National Association of Manufacturers and the Wetlands America Trust. He is a member of the executive committee of the Business Roundtable and a member of the Business Council.
Franklyn G. Prendergast, M.D., Ph.D.
Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics
Mayo Medical School
Franklyn G. Prendergast, M.D., Ph.D. is Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Professor of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School; and director, Mayo Clinic Center for Individualized Medicine. He was elected to the board of directors of Eli Lilly and Company in 1995.
Born in Linstead, Jamaica, he received a degree in medicine from the University of the West Indies in 1968. A Rhodes Scholar, he received a bachelor of arts degree in physiology from Oxford University in 1971, his doctorate in biochemistry from the University of Minnesota in 1977, and a master’s degree in physiology from Oxford University in 1979.
Prendergast began his career at the Mayo Medical School as an instructor in physiology in 1975. In 1977 he became associate consultant in pharmacology at the Mayo Foundation and assistant professor in pharmacology of the Mayo Medical School. Three years later he was named consultant in pharmacology at the Mayo Foundation and associate professor in pharmacology at the Mayo Medical School. In 1985 he became consultant and chair of the department of biochemistry and molecular biology for the Mayo Foundation. He became professor in pharmacology and professor in biochemistry and molecular biology at the Mayo Medical School in 1986. He was named director of research for Mayo Rochester in 1992. He is an emeritus member of the board of governors, Mayo Clinic Rochester; the board of governors, Mayo Clinic; and the board of trustees, Mayo Clinic.
Prendergast has been the recipient of numerous honors and awards, including Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology (1987); Mayo Distinguished Investigator (1988); distinguished alumnus, University of Minnesota and University of the West Indies; and honorary doctorates, Purdue University and University of the West Indies. He is a member of the American Chemical Society, American Association for the Advancement of Science, Biophysical Society, Sigma Xi, the American Society for Biochemistry and Molecular Biology, and the American Cancer Society.
Marschall S. Runge, M.D., Ph.D.
Executive Dean and Chair, Department of Medicine
University of North Carolina School of Medicine
Marschall S. Runge, M.D., Ph.D., is executive dean and chair of the Department of Medicine at the UNC School of Medicine, where he is instrumental in guiding the academic and clinical leadership of the School of Medicine and the UNC Health Care System. He is also principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS) Institute at UNC-Chapel Hill, one of fifty-five medical research institutions across the country funded by the Clinical and Translational Science Awards. He was elected to the board of directors of Eli Lilly and Company in 2013.
An honors graduate of Vanderbilt University with a bachelor of arts in biology and a doctorate in molecular biology, Dr. Runge earned his doctor of medicine degree from the Johns Hopkins School of Medicine, where he was an intern and resident in internal medicine. He then completed a cardiology fellowship at Harvard’s Massachusetts General Hospital and was a faculty member there prior to becoming an associate professor of medicine at Emory University in 1989.
Before joining the UNC faculty in 2000, Dr. Runge held the John Sealy Distinguished Centennial Chair in Internal Medicine and was director of the Division of Cardiology and the Sealy Center for Molecular Cardiology at the University of Texas Medical Branch at Galveston.
Kathi P. Seifert
Retired Executive Vice President
Kathi P. Seifert, retired executive vice president for Kimberly-Clark Corporation, was elected to the board of directors of Eli Lilly and Company in 1995.
A native of Appleton, Wisconsin, she received a bachelor of science degree from Valparaiso University.
Prior to joining Kimberly-Clark in 1978, Seifert held management positions at Procter & Gamble, Beatrice Foods, and Fort Howard Paper Company. She joined Kimberly-Clark as a product manager and held several marketing positions before being elected to executive vice president in November 1999. She retired in June 2004.
Seifert is chairman of Katapult, LLC and is a member of the board of directors of Supervalu Inc., Revlon Consumer Products Corporation, Lexmark International, Inc., Appleton Papers Inc., the U.S. Fund for UNICEF, and the Fox Cities Performing Arts Center.
Former Vice Chairman and Chief Executive Officer
DBS Group Holdings Ltd. and DBS Bank Ltd.
Jackson Tai, former vice chairman and chief executive officer, DBS Group Holdings Ltd and DBS Bank Ltd, was elected to the Eli Lilly and Company board of directors in November 2013.
In 1999, Tai joined DBS Group and DBS Bank (formerly the Development Bank of Singapore), one of the largest financial services groups in Asia, as chief financial officer. He served DBS as president and chief operating officer from 2001 to 2002, and as vice chairman and chief executive officer from 2002 to 2007.
From 1974 to 1999, Tai was an investment banker with J.P. Morgan & Co. Incorporated. Among his assignments at J.P. Morgan, Tai was senior regional officer and head of investment banking for Asia Pacific, based in Tokyo; global head of real estate investment banking, based in New York; senior regional officer and head of investment banking for the Western United States, based in San Francisco; and executive director of J.P. Morgan Securities, based in Tokyo.
Tai serves as a non-executive director of The Bank of China Limited, Singapore Airlines, MasterCard Incorporated, and Royal Philips NV. Tai serves as a trustee of Rensselaer Polytechnic Institute and a director of the Committee of 100.